BCL2 and acute lymphoblastic leukemia: Combining molecular-cytogenetic and Drug Sensitivity and Resistance Profiling (DSRP) studies, we confirmed BCL2 over-expression in three cases of immature T-ALL, and used this marker to prioritize the selection of the most effective compounds, as identified by DSRP.